Page last updated: 2024-11-10

fr 173657

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FR 173657: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5311108
CHEMBL ID130517
SCHEMBL ID3718364
SCHEMBL ID1559539
MeSH IDM0274776

Synonyms (32)

Synonym
(e)-3-(6-acetamidopyridin-3-yl)-n-[2-[[2,4-dichloro-3-[(2-methylquinolin-8-yl)oxymethyl]phenyl]-methylamino]-2-oxoethyl]prop-2-enamide
gtpl674
fk-3657
fr-173657
fr173657
fr 173657
L015626
CHEMBL130517 ,
(e)-3-(6-acetamidopyridin-3-yl)-n-[2-[2,4-dichloro-n-methyl-3-[(2-methylquinolin-8-yl)oxymethyl]anilino]-2-oxoethyl]prop-2-enamide
(e)-3-(6-acetylamino-pyridin-3-yl)-n-({[2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-phenyl]-methyl-carbamoyl}-methyl)-acrylamide
bdbm50067301
3-(6-acetamidopyridin-3-yl)-n-(2-((2,4-dichloro-3-((2-methylquinolin-8-yloxy)methyl)phenyl)(methyl)amino)-2-oxoethyl)acrylamide
SCHEMBL3718364
8-[3-[n-[(e)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-n-methylamino]-2,6-dichlorobenzyloxy]-2methylquinoline
8-[3-[n-[(e)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-n-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline
XCKWRUGRUFVXGC-NTEUORMPSA-N ,
8-[3-[n-[(e)-3-(6-acetamidopyridin-3-yl)acryloyl-glycyl]-n-methylamino]-2,6-dichlorobenzyloxy]-2-methyl-quinoline
SCHEMBL1559539
(e)-3-((6-acetamido-3-pyridyl)-n-(n-(2,4-dichloro-3-((2-methyl-8-quinolinyl)oxymethyl)phenyl)-n-methyl)aminocarbonyl methyl)acrylamide
fk 3657
262al91j0y ,
unii-262al91j0y
167838-64-4
Q27077731
2-propenamide, 3-(6-(acetylamino)-3-pyridinyl)-n-(2-((2,4-dichloro-3-(((2-methyl-8-quinolinyl)oxy)methyl)phenyl)methylamino)-2-oxoethyl)-, (2e)-
199791-42-9
(2e)-3-(6-(acetylamino)-3-pyridinyl)-n-(2-((2,4-dichloro-3-(((2-methyl-8-quinolinyl)oxy)methyl)phenyl)methylamino)-2-oxoethyl)-2-propenamide
(e)-3-(6-acetamidopyridin-3-yl)-n-(2-((2,4-dichloro-3-(((2-methylquinolin-8-yl)oxy)methyl)phenyl)(methyl)amino)-2-oxoethyl)acrylamide
(2e)-3-[6-(acetylamino)-3-pyridinyl]-n-[2-[[2,4-dichloro-3-[[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl]-2-propenamide
DTXSID401101144
2-propenamide, 3-[6-(acetylamino)-3-pyridinyl]-n-[2-[[2,4-dichloro-3-[[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl]-, (2e)-
AKOS040745795

Research Excerpts

Overview

FR 173657 acts as a competitive antagonist over an extended range of concentrations on human and rabbit B2 receptors. On pig and guinea pig receptors it depresses the maximal effect of bradykinin and thus appears to act as a noncompetitive antagonist.

ExcerptReferenceRelevance
"FR 173657 acts as a competitive antagonist over an extended range of concentrations on human and rabbit B2 receptors, whereas on pig and guinea pig receptors, it depresses the maximal effect of bradykinin and thus appears to act as a noncompetitive antagonist."( FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study.
Calò, G; Gobeil, F; Inamura, N; Regoli, D; Rizzi, A, 1997
)
2.46

Dosage Studied

ExcerptRelevanceReference
" FR167344 and FR173657 inhibited the B2 receptor-mediated phosphatidylinositol (PI) hydrolysis and produced a concentration-dependent rightward shift in the dose-response curve to bradykinin."( Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.
Aramori, I; Asano, M; Iwami, M; Kojo, H; Morikawa, N; Nakamura, K; Notsu, Y; O'Donnell, N; Zenkoh, J, 1997
)
0.3
" FK3657 shifted the intraurethral pressure dose-response curve for bradykinin to the right in rats."( Physiological Roles of Bradykinin and Involvement of Bradykinin B2 Receptor in Urethral Function in Humans and Animals.
Fujimoto, K; Masuda, N; Nakajima, S; Takeda, M; Yoshino, T; Yuyama, H, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.00140.00031.38338.4000AID43158
B2 bradykinin receptorHomo sapiens (human)IC50 (µMol)0.00140.00040.02120.2800AID421293; AID43150; AID43158
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
smooth muscle contractionB2 bradykinin receptorHomo sapiens (human)
inflammatory responseB2 bradykinin receptorHomo sapiens (human)
cell surface receptor signaling pathwayB2 bradykinin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayB2 bradykinin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationB2 bradykinin receptorHomo sapiens (human)
blood circulationB2 bradykinin receptorHomo sapiens (human)
response to salt stressB2 bradykinin receptorHomo sapiens (human)
regulation of vasoconstrictionB2 bradykinin receptorHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationB2 bradykinin receptorHomo sapiens (human)
vasoconstrictionB2 bradykinin receptorHomo sapiens (human)
vasodilationB2 bradykinin receptorHomo sapiens (human)
regulation of vascular permeabilityB2 bradykinin receptorHomo sapiens (human)
arachidonic acid secretionB2 bradykinin receptorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorB2 bradykinin receptorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorB2 bradykinin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protease bindingB2 bradykinin receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityB2 bradykinin receptorHomo sapiens (human)
bradykinin receptor activityB2 bradykinin receptorHomo sapiens (human)
protein bindingB2 bradykinin receptorHomo sapiens (human)
type 1 angiotensin receptor bindingB2 bradykinin receptorHomo sapiens (human)
protein heterodimerization activityB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeB2 bradykinin receptorHomo sapiens (human)
Golgi apparatusB2 bradykinin receptorHomo sapiens (human)
plasma membraneB2 bradykinin receptorHomo sapiens (human)
intracellular membrane-bounded organelleB2 bradykinin receptorHomo sapiens (human)
plasma membraneB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1728101Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs2021European journal of medicinal chemistry, Jan-15, Volume: 210Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
AID75892Antagonistic activity in inhibiting BK-induced bronchoconstriction in guinea pigs by oral administration at 1 mg/kg dose.1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
AID43138Inhibition of the specific binding of [3H]BK to Bradykinin receptor B2 in guinea pig ileum membrane preparations1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
AID76189In vivo inhibition of Bradykinin induced Bronchoconstriction in anaesthetized guinea pig following 1 mg/kg p.o.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
AID43150Inhibition specific binding of [3H]BK (1.0 nM) to human Bradykinin receptor B2 which was expressed in CHO (Chinese hamster ovary) cells by 50%.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
AID43129Concentration required to inhibit specific binding of [ 3H]BK (0.06 nM) to Bradykinin receptor B2 in guinea pig ileum membrane preparations by 50%.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
AID421293Displacement of [3H]bradykinin from human recombinant B2 receptor expressed in HEK293 cells2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Novel small molecule bradykinin B2 receptor antagonists.
AID77877Inhibition of Bradykinin induced Bronchoconstriction in anaesthetized guinea pig at 0.32mg/kg, po1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
AID43158Inhibition of the specific binding of [3H]BK to human recombinant Bradykinin receptor B2 expressed in CHO cells.1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
AID1346473Human B2 receptor (Bradykinin receptors)1997Molecular pharmacology, Feb, Volume: 51, Issue:2
Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.
AID1346473Human B2 receptor (Bradykinin receptors)1997Hypertension (Dallas, Tex. : 1979), Apr, Volume: 29, Issue:4
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (33.33)18.2507
2000's40 (57.97)29.6817
2010's5 (7.25)24.3611
2020's1 (1.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.07 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (94.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]